
Navigating the Prescription Journey

patient ∂ccess™

Learn how you can support patients prescribed CIBINQO® (abrocitinib) or LITFULO™ (ritlecitinib) with commercial insurance on their prescription fulfillment journey with Pfizer Dermatology Patient Access (PDPA). Use this piece as a guide for key reminders, and learn more information about steps 1-6 on the next page.



*For eligible patients. Terms and conditions apply and are subject to change at any time.

Please see full <u>Prescribing Information</u>, including **BOXED WARNING**, and <u>Medication Guide</u> for CIBINQO, and full <u>Prescribing Information</u>, including **BOXED WARNING**, and <u>Medication Guide</u> for LITFULO.

Access Journey Reminders

Use this piece as a guide for key reminders and to learn more information about steps 1-6.



1 Enrollment	Benefits Investigation	Prior Authorization (PA) Assistance	4 Appeals Assistance	Interim Care Rx Program	Rx Triaged to Pharmacy
Porms: Note all required fields on enrollment form; obtain all patient and Healthcare Provider signatures and dates Patient contact: Confirm patient's preferred contact number and inform patient they will be contacted for information by PDPA (HUB) and/or a Patient Access Coordinator (if they've completed the opt-in form at PACpdpa.com or on the enrollment form) Office contact: PDPA will need a direct point of contact for patient case communication. Please include on enrollment form	Timing: PDPA will inform you of Payor requirements by fax, typically within 24 hours Contact: PDPA and/or a Patient Access Coordinator will be contacting the patient directly to explain the post prescription journey Note: If PDPA cannot verify the patient's insurance, they will reach out to you or the patient for additional information	 Prior to submitting: Check for insurance criteria or necessary information the Payor is requesting Inform: When a determination has been made, inform PDPA by fax or phone Approved: If approved, the prescription will be triaged to the pharmacy for fulfillment Denied: If denied, work with PDPA to discuss next steps for this patient 	Update: Inform PDPA that you will appeal a denied PA by phone or fax Address: Address the PA denial reason in your appeal Inform: When a determination has been made, inform PDPA by fax or phone	• Eligible: If a delay or coverage denial occurs during the prior authorization or appeals process, eligible, commercially insured patients enrolled in PDPA may receive CIBINQO® (abrocitinib) or LITFULO™ (ritlecitinib) for up to 2 years at no cost, shipped to them through the Interim Care Rx program* • Communication: PDPA will determine if the patient is eligible and contact you to enroll the patient in the Interim Care Rx program if not initially requested on the enrollment form *For eligible, commercially insured patients only. Not available to residents in the states of MA, MI, MN, or RI. Additional restrictions apply. See terms and conditions. Subject to change at any time.	Specialty pharmacy: Ensure the patient knows the Specialty Pharmacy name and phone number. Copay: Check to see if the patient is eligible for the Copay Savings Card Program† at PDPAcopaycard.com Remind: Remind the patient that their Specialty Pharmacy will be contacting them and it is important that patients promptly return any outreach †Eligibility required. No membership fees. This is not health insurance. Only for use with commercial insurance. If patients are enrolled in a state or federally funded prescription insurance program, they may not use the copay card. See terms and conditions at PDPAcopaycard.com.



Visit <u>PfizerDermatologyPatientAccess.com</u> for additional resources, forms, copay cards, and to connect with your local FRM.



Please see full <u>Prescribing Information</u>, including **BOXED WARNING**, and <u>Medication Guide</u> for CIBINQO, and full <u>Prescribing Information</u>, including **BOXED WARNING**, and <u>Medication Guide</u> for LITFULO.

